No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
IKT Inhibikase Therapeutics
- 1.5950
- -0.0350-2.15%
Close Jun 11 16:00 ET
11.51MMarket Cap-480P/E (TTM)
1.6651High1.5300Low12.46KVolume1.5600Open1.6300Pre Close19.53KTurnover0.20%Turnover RatioLossP/E (Static)7.22MShares4.176052wk High1.70P/B10.07MFloat Cap0.790052wk Low--Dividend TTM6.32MShs Float70.8000Historical High--Div YieldTTM8.29%Amplitude0.7900Historical Low1.5660Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Maxim Group Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $8
Maxim Group analyst Jason McCarthy maintains $Inhibikase Therapeutics(IKT.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 29.
Express News | Inhibikase Therapeutics Announces Expansion Into Cardiopulmonary Disease
Express News | Inhibikase Therapeutics Inc: Will Submit Ind Application to FDA for Ikt-001Pro as Treatment for Pulmonary Arterial Hypertension Early in Q3
Express News | Inhibikase Therapeutics Inc: Scaling Process Development Efforts for Ikt-001Pro to Support Late-Stage Clinical Development & Nda Batch Requirements
Express News | Inhibikase Therapeutics Inc: Will Discontinue Development of Treatments for Progressive Multifocal Leukoencephalopathy
Express News | Inhibikase Therapeutics Announces Expansion to Its Therapeutic Pipeline and Updates Its Research and Development Programs
Comments
$Inhibikase Therapeutics(IKT.US$
NEWS
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
NEWS
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
$Inhibikase Therapeutics(IKT.US$ Reuters· 6 mins ago
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
$Inhibikase Therapeutics(IKT.US$ Inhibikase Therapeutics Inc - FDA Indicated Ikt-001Pro Is Eligible for Exclusivity Designations in Pulmonary Arterial Hypertension
1
$Inhibikase Therapeutics(IKT.US$
NEWS
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced outcomes from the final pre-IND meeting with the FDA for IkT-001Pro as a treatment for Pulmonary Arterial Hypertension. The FDA designated IkT-001Pro as a New Molecular Entity, allowing for exclusivity designations. The Company is preparing the IND application for Pro, a pote...
NEWS
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced outcomes from the final pre-IND meeting with the FDA for IkT-001Pro as a treatment for Pulmonary Arterial Hypertension. The FDA designated IkT-001Pro as a New Molecular Entity, allowing for exclusivity designations. The Company is preparing the IND application for Pro, a pote...
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg